Registry following adults with severe asthma treated with biologic medicines in Taiwan
Records real-world results of biologic asthma medicines in adults with severe asthma.
Plain-language title generated from the registry record
Registry title: Taiwan Severe Asthma Biologic Registry
Key facts
- Where
- Taichung, TaiwanSee the site
Where in Taiwan
- Taichung Veterans General HospitalTaichung, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Taichung Veterans General Hospital
- Trial code
- NCT06456450
- Record updated
- 19 May 2026
- Original description
This is a prospective multi-centers cohort study for registration adult patients with severe asthma and were reimbursed biologics treatment in Taiwan.Read full original descriptionShow less
Taiwan Severe Asthma Biologic Registry
This is a prospective multi-centers cohort study for registration adult patients with severe asthma and were reimbursed biologics treatment in Taiwan.
The goal of this observational study is to discover the real-world effectiveness, the impact of initiating, switching of biologics, and the possible prediction factors for selecting the best treatment option for patients.
The main question[s] it aims to answer are:
1. Determine risk factors associated with poor asthma control. 2. Support the development of effectiveness and safety of therapeutic principles 3. To discover the real-world effectiveness of different biologics ( Clinical remission) 4. To discover the impact of initiating biologics for severe asthma patients. 5. To evaluate the prevalence of biologics switching and its benefits for patients. 6. To compare the achievement rate of clinical remission among different biologics.
Participants who are treated either with omalizumab, mepolizumab, benralizumab dupilzumab or Tezepelumab after January 1, 2020 will be included in the study.
Inclusion: Provision of informed consent prior to any study specific procedures; Patient should be reviewed as well as confirmed by the National Health Insurance Administration (NHIA) or by the study board member as a Severe Asthma case; Female and male aged over 18 years old; Patients who are treated either with omalizumab, mepolizumab, or benralizumab after January 1, 2020.
Exclusion: The washout period should be at least 12 months. In other words, the enrolled patients should have no experience in receiving a biological treatment or in participating relative clinical trial before his/her biologic initiation; History of Biologic usage before January 1, 2020, should be ruled out; Comorbid pulmonary diseases (e.g.: Chronic Obstructive Pulmonary Disease, Bronchiectasis, Pulmonary Fibrosis, etc.) or risk factors (e.g.: smoking or environmental exposure, etc..) that could be associated with pulmonary or systemic diseases, other than Asthma; Lack of informed consent for participation.